Long-term survival in AIDS-related primary central nervous system lymphoma
Open Access
- 30 August 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (1) , 99-108
Abstract
Background.: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention.Methods.: To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies. Results were validated in a retrospective, multicenter analysis that evaluated all newly diagnosed patients with AR-PCNSL treated with cART plus high-dose methotrexate (HD-MTX).Results.: We provide evidence that CD4+ reconstitution with cART administered during HD-MTX correlates with long-term survival among patients with CD4 <100. This was confirmed in a multicenter analysis which demonstrated that integration of cART regimens with HD-MTX was generally well tolerated and resulted in longer progression-free survival than other treatments. No profound differences in immunophenotype were identified in an analysis of AR-PCNSL tumors that arose in the pre- versus post-cART eras. However, we detected evidence for a demographic shift, as the proportion of minority patients with AR-PCNSL increased since advent of cART.Conclusion.: Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL.Keywords
Funding Information
- National Institutes of Health
This publication has 46 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell LymphomasPLOS ONE, 2012
- How I treat HIV-associated lymphomaBlood, 2012
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and TemozolomideClinical Cancer Research, 2011
- Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life AnalysisJournal of Clinical Oncology, 2011
- Trust in Physicians and Racial Disparities in HIV CareAIDS Patient Care and STDs, 2010
- Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaBlood, 2010
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapyBlood, 2009
- Race/Ethnicity and Risk of AIDS and Death Among HIV-infected Patients with Access to CareJournal of General Internal Medicine, 2009
- Epstein–Barr virus associated lymphoproliferations in the AIDS settingEuropean Journal of Cancer, 2001